INTRODUCTION
Cancer is the uncontrolled growth and spread of cells. Annually, 8.2 million deaths are attributable to cancer, an estimated 13% of all deaths worldwide, and breast cancer accounts for over half a million of these. The total number of new cases is expected to rise by 70% over the next two decades [1] . The continuous development of new, cost-effective drug therapies is crucial to increase the range of options available to patients, and to improve their long-term prognosis.
Piperlongumine (also known as piplartine, 1, Figure 1) is an alkaloid isolated from a number of Piper plant species, including the long pepper plant Piper longum L. It has a large number of reported uses in traditional medicine, and has demonstrated cytotoxic and antitumour activity [2] .
In particular, it was found to be selectively toxic to cancer cells by increasing the level of reactive oxygen species (ROS) and inducing apoptotic cell death, although the exact mechanisms of action remain unclear [3] . Compound 1 has been recently reported to be a direct STAT3 inhibitor [4] , a proteasome inhibitor [5] , to promote autophagy [6] , and to modulate NF-κB and NF-κB-regulated gene products [7] .
Compound 1 is a chalcone-type molecule, consisting of two ring systems linked by a α-βunsaturated carbonyl chain. One of the rings is aromatic and substituted with three methoxy groups, while the second is a piperidinone-type ring containing a conjugated alkene. Compound 1 is structurally similar to a number of known tubulin-targeting antiproliferative compounds. These include combretastatin A-4 (2) and chalcone 3 (Figure 1 ), both containing a trimethoxyphenyl moiety [8] . An analogue of 2 with a substituted pyridone ring (4, Figure 1 ) also displays potent antitubulin activity [9] . A hybrid of compounds 1 and 2 was recently reported as a tubulin depolymerising agent [10] . Considering these results, we undertook to investigate if 1 has inherent tubulin-and microtubule-targeting activity in breast cancer cells. We also synthesised a number of analogues of 1 to investigate structure-activity relationships of the trimethoxyphenyl group of 1 on the antiproliferative potency in breast cancer cells.
RESULTS and DISCUSSION

Chemistry
Previous research has examined the structure-activity relationships of the piperidinone ring of 1 [11] . Hence, we sought to examine the effects of modifying the trimethoxyphenyl ring. The trimethoxyphenyl ring has repeatedly been shown to be crucial for the tubulin-depolymerising ability of a number of compounds, including colchicine, podophyllotoxin and 2 [12] [13] [14] . These trimethoxyphenyl-containing compounds bind at the colchicine-binding site on tubulin, mainly located in the β-subunit. A number of analogues of 1 with different substituents were chosen for synthesis, in order to better understand the contribution of the trimethoxyphenyl ring to the antiproliferative activity of 1. Synthesis was achieved in two steps via the key intermediate 5,6dihydropyridin-2(1H)-one. 5,6-Dihydropyridin-2(1H)-one (6) was synthesised in two steps from but-3-en-1-amine via N-(but-3-en-1-yl)acrylamide (5) (Scheme 1, steps i and ii). Compound 1 and seven analogues (7) (8) (9) (10) (11) (12) (13) were obtained in moderate yields via a one-pot reaction between 6 and appropriately substituted cinnamic acids, pre-activated with pivaloyl chloride (Scheme 1, steps iii and iv, 61-72% yield) [15] . unsaturated double bond. An X-ray crystallographic study of 12 confirmed the structure, featuring a non-planar piperidinone ring and a 3,4-dimethoxyaryl ring ( Figure 2 ). The length of the double bond in the lactam ring agrees with the published structure for 1 (1. 329 Å compared to 1.322 Å) [16] . The C-N bonds in the lactam ring are unequal with lengths of 1.482 Å (C1-N6) compared to 1.390 Å (C5-N6). The 3-methoxy and 4-methoxy groups are approximately co-planar with the aromatic ring (torsion angles 5.6 (2)° and 176.8 (13)° respectively). The linear α,β-unsaturated double bond adopts the predicted trans configuration, with a bond length of 1.335 Å (1.329 Å reported) [16] .
Biochemistry
Cell Viability
Compound 1 was first tested for its effects on viability in two human cell lines, MCF-7 breast cancer cells and Jurkat T-lymphocytes. The concentration of 1 required to inhibit the growth of MCF-7 and Jurkat cells by 50% (IC50) was determined to be 1.2 ± 0.6 μM and 1.4 ± 0.3 μM respectively at 48 hr ( Figure 3A ). These are similar to previously reported values for 1 (8 μM in MCF-7 cells and 5 μM in Jurkat cells) [17, 18] . Cell viability results for 1 in a large number of cancer cell lines have been determined and, in general, IC50 values range between 1-10 μM [2] .
IC50 values for compounds 7-13 were found to be between 3.4 and 9.6 μM in MCF-7 cancer cells, with 7, 12 and 13 showing the best activity (IC50 values of 3.5, 3.7 and 3.4 μM respectively)( Table   1 ). Mono-methoxylated compounds 8, 9 and 10 showed decreased potency indicating that one methoxy group is detrimental to antiproliferative activity, regardless of its position on the ring (2-, 3-, or 4-methoxy). Comparison of di-methoxylated compounds 11 and 12 reveals that a 2,3methoxy substitution pattern is preferable to 1,3-methoxy (IC50 values of 8.5 and 3.7 μM respectively). These analogues were also assessed for toxicity using non-tumorigenic MCF-10a mammary epithelial cell line ( Figure 3B and Figure S1, Supporting Information). None of the compounds had any effect on viability of MCF-10a cells at a concentration of 1 μM (24 and 48 hr) and minimal effects were noted at 5 μM (>90% viability for all compounds at 24 hr, and >80% viability at 48 hr). The best selectivity at 5 μM was observed for compounds 7, 12 and 13 (differences of 53, 46 and 48% in cell viability of MCF-10a compared to MCF-7, respectively).
Significant effects on MCF-10a cell viability were observed at 10 μM, equal to the effect on MCF-7 viability in most cases. Treatment with 1 (10 μM) caused a 90% reduction in cell viability. This indicates poor selectivity for cancer cells at this concentration, with the exception of compound 13. Compound 7 showed the highest toxicity at 48 hr ( Figure 3B ). On the basis of combined results in MCF-7 and MCF-10a cells, compounds 12 and 13 were identified as the best candidates for future development.
Effect of Pre-treatment with Antioxidants on Cellular Viability
Compound 1 has been reported as an agent that increases the level of ROS in cells [3] . To investigate the potential effects of our analogues 7-13 on ROS levels in MCF-7 breast cancer cells, we employed a viability assay in which cells are pre-incubated with an antioxidant prior to treatment with the compound of interest ( Figure 4 ). This assay indicates potential involvement of ROS in a compound's mechanism of action. Two antioxidants were used: N-acetyl cysteine (NAC) and the vitamin E derivative Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).
The antioxidant concentrations used were shown to have no effect on cell viability. Trolox (100 μM and 300 μM) has been shown to be an effective antioxidant in MDA-MB-231 breast cancer cells and MIA PaCa-2 pancreatic cancer cells [19] . We also evaluated a number of known tubulindestabilising agents [colchicine, 2 and four chalcones (14-17, Figure 5 )]. These compounds were chosen on the basis of structural similarity to 1 (all with the exception of colchicine contain a linear double bond linking two ring systems, one of which is substituted with 2 or more methoxy groups), antiproliferative potency, and tubulin-targeting activity. These chalcones were synthesised and characterised by published procedures (compound 14 [8] , 15 [20] , 16 [8] , 17 [21] ).
Firstly, the effects of 1 and representative compounds 7, 12 and 13, alone and in combination with NAC and Trolox were assessed. Pre-treatment for 1 hr with NAC has a dramatic protective effect on MCF-7 cells at all concentrations of all compounds tested ( Figure 4 ). Viability increases were generally greater than 50%, with the highest increase of 73% (compound 7, 10 μM). No significant increases in cell viability were noted when cells were pre-treated with Trolox. Similar results show that pre-treatment with NAC but not Trolox has an effect on activity of 1 [19] . Compound 1 is a relatively reactive compound, due to the reactive α,β-unsaturated carbonyl system contained in the piperidinone ring. It has been shown to directly bind to NAC (200 equiv. in Hepes buffer; 24 hr reaction) [19] and to the small-molecule thiol methyl thioglycolate (3 equiv. in DMSO; 72 hr reaction) [11] . It is possible that this reaction occurs in the aqueous media of cell viability assay, thus inactivating the α,β-unsaturated carbonyl group of 1. This reaction is not possible with Trolox.
The same considerations apply to analogues 7, 12 and 13. This is a potential reason for the different effects observed with the two different antioxidants. The differing concentrations of NAC and Trolox may also play a part.
Secondly, effects of antioxidant pre-treatment on cell viability were assessed for known tubulintargeting compounds. Cells pre-treated with NAC showed increased viability for all compounds compared to cells that were not pre-treated ( Figure 6 ). Highest increases were noted for 2 (100 nM; 22%) and chalcone 14 (35%). Increases in viability were greater than 10% for all concentrations of the six compounds evaluated. Similar results were obtained for a lower concentration of 16 and 17 (1 μM; data not shown). Cells pre-treated with Trolox showed slightly increased viability but effects were generally minimal ( Figure 6 ). The highest increase in viability was 11.4% for 2 (10 μM). Viability was increased by less than 10% for chalcones 14-17.
The results from the viability assay of colchicine, 2 and chalcones 14-17 indicate potential ROS involvement in cancer cell death. This has not been reported for 2 or chalcones 14-17 previously and is worthy of further investigation. A number of known tubulin-targeting agents also have effects on reactive oxygen species in cells. Paclitaxel, a microtubule-stabilising agent, has been reported to generate ROS by activating plasma-membrane associated NADPH oxidase (NOX) [22] . Vinca alkaloids, clinically used microtubule-destabilising agents, induce apoptosis in lung adenocarcinoma cells via ROS accumulation [23] . Isothiocyanates known to induce oxidative stress have subsequently been shown to induce degradation of cellular tubulin by proteasomes [24] . An analogue of colchicine, Green-1, was reported as increasing ROS production in pancreatic cancer cells and leukaemia cells but its structural modification led to loss of its ability to depolymerise tubulin [25] . It appears that there is a link between ROS levels and the behaviour of microtubules in cells. Given the advanced status of 2 in phase II clinical trials, it is important to fully elucidate its cellular effects [21] . [26] . Compound 1 also reportedly induces both apoptosis and necrosis in leukaemia cell lines [17] , and apoptosis in Burkitt lymphoma cell lines [27] , prostate cancer cells [28] , and triple-negative breast cancer cells [18] .
Effects of Piperlongumine on the Cell Cycle and Apoptosis
Tubulin-destabilising agents often cause increased cell accumulation in the G2/M phase, due to defective mitotic checkpoints, as found for 1 in MCF-7 cells above. A number of previous studies have noted G2/M arrest upon treatment with 1, including in Chinese hamster lung fibroblasts (V79), [29] OVCAR3 human ovarian cancer cells [30] and PC-3 prostate carcinoma cells [28] .
This suggests that 1 may potentially target tubulin. The structural similarity of 1 to a number of known tubulin-destabilizing agents ( Figure 1 ) strengthens this hypothesis. To investigate further, specific tubulin assays were performed.
Effects of Piperlongumine on Tubulin Polymerisation and Interaction with Colchicine-
Binding Site
The tubulin-targeting properties of 1 were firstly examined in vitro using isolated bovine tubulin ( Figure 8A ). The effect of test compounds 1 and 7 on tubulin polymerization was determined by reading absorbance at 340 nm over 60 min, as the extent of light-scattering by microtubules is proportional to their degree of polymerisation [31] . Paclitaxel, a known microtubule-stabilising agent, was used as a control and increased the final polymer mass ( Figure 8A ). Depolymerisation of tubulin and reduction in the final polymer mass was noted for the higher concentration of 1 (25 μM, Figure 8A ). A similar but less pronounced effect was seen for compound 7 (25 μM).
Compound 1 was selected for further investigation in MCF-7 breast cancer cells and Jurkat Tlymphocytes.
A cellular assay based on sedimentation followed by western blotting were used to examine the effects of 1 on tubulin polymerisation in both MCF-7 and Jurkat cells ( Figure 8B ). Polymerized and depolymerized microtubules have different solubilities and localize preferentially in the pellet or supernatant of lysed, centrifuged cells, respectively [32] . Paclitaxel (a microtubule-stabilising agent) and nocodazole (a microtubule-destabilising agent) were used as controls. As expected, tubulin from nocodazole-treated cells was depolymerized and detected almost wholly in the supernatant, whereas tubulin from paclitaxel-treated cells was polymerized and detected solely in the pellet ( Figure 8B ). Tubulin from cells treated with 1 (10 μM) was found exclusively in the supernatant, indicating complete depolymerization of tubulin ( Figure 8B ). Similar results were obtained for 5 μM and 20 μM concentrations of 1. Equal amounts of tubulin were detected in the supernatants and pellets of cells treated with 1 μM of 1, indicating that this concentration does not have an effect on tubulin polymerization in MCF-7 and Jurkat cells (data not shown).
Finally, a second cellular assay to examine the effects of 1 on the microtubule network of MCF-7 cells was carried out using immunofluorescence and confocal microscopy. Cells were again treated with either paclitaxel, known microtubule-destabilising agent 2, or 1. Vehicle-treated cells displayed organised microtubule structures ( Figure 9 ). Cells treated with the microtubulestabilising agent paclitaxel exhibited characteristic bundling, whereas cells treated with 2 showed disruption of the microtubule network. Cells treated with a higher concentration of 1 (20 μM) showed a disorganised microtubule structure, consistent with depolymerised tubulin. A lower concentration of 10 μM caused less depolymerisation, with some polymerised microtubules still present ( Figure 9 ). These results provide further evidence that 1 is a direct microtubuledestabilising agent.
Compound 1 is structurally similar to a number of tubulin-depolymerising agents, including 2, which bind to the colchicine-binding site on tubulin. Potential binding of 1 at the colchicinebinding site was therefore investigated using a whole-cell based assay. N,N'-Ethylenebis(iodoacetamide) (EBI) is an alkylating agent that cross-links cysteine residues at positions 239 and 354 in the colchicine-binding site of tubulin, forming a β-tubulin-EBI adduct. This adduct is detectable by Western blotting as an immunoreactive band that migrates faster than β-tubulin.
Microtubule-destabilising agents that bind at the colchicine-site, such as 2, prevent the formation of the β-tubulin-EBI adduct [33] . MCF-7 cells were treated with vehicle control, 2 (10 μM) or 1 (40 μM) for 2 h, followed by EBI for an additional 1.5 h ( Figure 10 ). Control samples show the presence of the β-tubulin-EBI adduct at a lower position, indicating that EBI has cross-linked Cys239 and Cys354 on β-tubulin. Adduct formation was inhibited in cells treated with 2, confirming that 2 binds to the colchicine-binding site, whereas 1 did not inhibit the formation of the β-tubulin-EBI adduct. Similar results were found in HT-29 cells ( Figure 10 ). This indicates that 1 does not bind at the colchicine-site of tubulin. It is also possible, due to the presence of reactive α,β-unsaturated groups, that compound 1 itself could cross-link cysteine residues on tubulin. It has a similar molecular weight to EBI (317 and 396 respectively) and so an adduct between β-tubulin and 1 would migrate a similar distance to that of a β-tubulin−EBI adduct.
Further work is required to determine where, and how, 1 interacts with tubulin. 
Conclusion
EXPERIMENTAL METHODS
All reagents were commercially available and were used without further purification unless otherwise indicated. Anhydrous dichloromethane was obtained by distillation from calcium hydride immediately prior to use. 1 Acryloylchloride (1.2 equiv., 1.6 mL, 16.90 mmol) was added and the mixture was allowed to stir at room temperature for 3 hr. The reaction mixture was diluted with water, and then extracted into DCM (2 × 10 mL). The solvent was removed in vacuo and the crude product was purified by flash column chromatography on silica gel using CH2Cl2: methanol (9:1) to give a yellow liquid (56% yield). 1 Ref. [15] ). Grubbs-II catalyst (42 mg, 5 mol %) was added to a solution of 5 (0.125 g, 1 mmol) in anhydrous DCM (160 mL) and refluxed for 6 hr under inert conditions. The mixture was stirred for an additional 1 hr at room temperature in open air to deactivate the catalyst. The reaction mixture was filtered through celite, concentrated, and the residue was purified by column chromatography on silica gel using hexane/EtOAc (1:1) to give a brown liquid (52% yield). 1 
5,6-Dihydropyridin-2(1H)-one (6)(
Synthesis of compounds 7-13.
General Method I: To a solution of cinnamic acid analogue (0.875 mmol), in freshly distilled THF (5 mL) was added triethylamine (0.10 mL). Pivaloyl chloride (0.69 mmol) was added at -20°C and the reaction mixture was stirred for 45 min. To a solution of 6 (1.05 mmol) in freshly distilled THF (5 mL) was added n-BuLi (1.2 equiv) at -78°C under inert atmosphere conditions and the reaction was stirred for 45 min. Then, anhydride prepared from the above step was added and the reaction mixture was stirred for 1h. The reaction mixture was quenched with saturated NH4Cl (2 mL), extracted with ethyl acetate (2  10 mL), the organic layer was separated and washed with sat. NaCl (2 x 6 mL) and dried over anhydrous Na2SO4. The residue was evaporated in vacuo to give a crude product which was finally purified by column chromatography on silica gel using hexane/EtOAc (6:4) as eluent to give yellow solid piperlongumine analogue.
1-Cinnamoyl-5,6-dihydropyridin-2(1H)-one (7)
was obtained from 6 and cinnamic acid as a colourless oil (72% yield). 1 13 
(E)-1-(3-(3-Methoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (9)
was obtained from 6 and 3-methoxycinnamic acid as a colourless oil (65% yield). 1 (1 H, m); 13 
(E)-1-(3-(2,4-Dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one (11) was
obtained from 6 and 2,4-dimethoxycinnamic acid as a yellow oil (63% yield). 1 1-(3-(3,4-Dimethoxyphenyl) 1-(3-(2,4,5-Trimethoxyphenyl) 
(E)-
Crystal Structure Report for Compound 12.
A specimen of C16H17NO4, approximate dimensions 0.050 mm x 0.140 mm x 0.300 mm, was used for the X-ray crystallographic analysis.
The X-ray intensity data were measured at 100(2)K using an Oxford Cryosystems low temperature device using a MiTeGen micromount. Bruker APEX software was used to correct for Lorentz and polarization effects. A total of 360 frames were collected. The total exposure time was 7.00 hours.
The integration of the data using a monoclinic unit cell yielded a total of 20430 reflections to a maximum θ angle of 26.80° (0.79 Å resolution), of which 2947 were independent (average redundancy 6.932, completeness = 99.5%, Rint = 6.24%, Rsig = 3.74%) and 2189 (74.28%) were greater than 2σ( at -20 °C for 24 hr. PBS (2 mL) and FBS (5 μL) were added and cell suspensions were centrifuged at 800g for 10 min. The supernatant was carefully removed and cells were resuspended in BD FACSflow (400 μL). Ribonuclease A (1 mg/mL; 25 μL) and propidium iodide (1 mg/mL; 75 μL) were added and the mixtures were incubated in the dark at 37 °C for 30 min. Samples were analysed using filter FL-2 on the BD Accuri C6 flow cytometer (BD Biosciences). Data collection was gated to exclude cellular debris and cell aggregates. At least 10,000 cells per sample were analysed. Data was analysed using BD CellQuest™. Experiments were performed on three independent occasions for determination of the mean values reported.
Tubulin Polymerization.
Tubulin polymerisation was carried out using an assay kit supplied by Cytoskeleton [Tubulin polymerization HTS assay using >97% pure porcine tubulin, OD-based (BK004P)], based on the principal that light is scattered by microtubules to an extent that is proportional to the concentration of the microtubule polymer. Compounds that interact with tubulin alter its polymerisation, and this can be detected using a spectrophotometer. The absorbance at 340 nm at 37°C is monitored. The assay was performed as described in version 2.2 of the tubulin polymerisation assay kit manual [31]. 
Sedimentation assay and western blotting (tubulin polymerisation).
